Blueprint Medicines Corporation(BPMC)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

BPMC iron condor setups BPMC expected move BPMC IV rank history

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$129.50
52-Week Range
$127.86 – $129.65
IV Rank (30D)
28.47
Straddle Price
$0.00
P/C Vol Ratio
0.43
Market Cap
$8.4B
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$8.4B

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operat…

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -1.38% 5
Feb -5.27% 5
Mar +1.80% 5
Apr +0.88% 5
May +6.01% 5
Jun +0.84% 5
Jul +0.86% 5
Aug +3.10% 4
Sep +0.21% 4
Oct -2.59% 4
Nov -0.84% 4
Dec +5.93% 4
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $128.60
SMA 50: $118.17
SMA 200: $99.43
Current: $129.46
EMA 12: $128.84
EMA 26: $126.04
MACD: 2.7992 | Signal: -0.8065
BULLISH
ADX (14): 52.21
STRONG TREND
+DI: 40.50
−DI: 10.66
Momentum Oscillators
RSI (14): 76.66
OVERBOUGHT
Stoch %K: 85.00
Stoch %D: 86.74
Williams %R: -11.95
Volume & Volatility
BB Upper: $129.60
BB Lower: $127.60
NEUTRAL
OBV: 21,735,489
Vol SMA 20: 4,470,336
Vol ROC: 28.60%
ATR: $0.86
True Range: $0.27
HV 20: 2.5%
HV 30: 2.6%
HV 60: 58.3%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:07.430000
Date Range: 2023-07-20T00:00:00 – 2025-07-17T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
4 of 4 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-01 Pre-Market 10.30% 7.49% 0.73x Within
2024-10-30 Pre-Market 12.58% 9.16% 0.73x Within
2025-02-13 Pre-Market 13.47% 7.28% 0.54x Within
2025-05-01 After-Close 8.07% 5.34% 0.66x Within
Options Activity
IV Rank (30D)
28.47
IV Rank (7D)
28.47
Avg IV
44.2%
Straddle (30D)
$0.00
Straddle (7D)
$0.00
P/C Volume
0.43
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

8 filers1,504 shares$177.68K value
# Filer Shares Value % of Total % of Float Period
1 Essential Partners LLC 878 $112.54K 63.34% — 2025-06-30
2 KELLEHER FINANCIAL ADVISORS 300 $38.45K 21.64% — 2026-03-31
3 DANSKE BANK A/S 300 $26.55K 14.94% — 2025-03-31
4 HUNTINGTON NATIONAL BANK Custodian 1 $129 0.07% — 2026-03-31
5 MassMutual Private Wealth & Trust, FSB 9 $0 0.00% — 2026-03-31
6 PRIVATE TRUST CO NA 1 $0 0.00% — 2026-03-31
7 Ascentis Independent Advisors Custodian 11 $0 0.00% — 2026-03-31
8 Keating Financial Advisory Services, Inc. 4 $0 0.00% — 2026-03-31
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2025-07-21
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-07-21 Percy H. Carter Chief Scientific Officer Mixed −53,155 — EDGAR
2025-07-21 Alexis Borisy Director Mixed −78,062 — EDGAR
2025-07-21 L. Becker Hewes Chief Medical Officer Mixed −30,419 — EDGAR
2025-07-21 Habib J Dable Director Mixed −12,644 — EDGAR
2025-07-21 Philina Lee Chief Commercial Officer Mixed −41,996 — EDGAR
2025-07-21 Jeffrey W. Albers Director Mixed −150,532 — EDGAR
2025-07-21 Tracey L McCain EVP & Chief Legal Officer Mixed −66,842 — EDGAR
2025-07-21 John Tsai Director Mixed −12,644 — EDGAR
2025-07-21 Ariel Hurley Principal Accounting Officer Mixed −17,064 — EDGAR
2025-07-21 Kate Haviland Chief Executive Officer Mixed −165,929 — EDGAR
2025-07-21 Fouad Namouni PRESIDENT, R & D Mixed −75,781 — EDGAR
2025-07-21 Daniella Beckman Director Mixed −14,744 — EDGAR
2025-07-21 Michael Landsittel Chief Financial Officer Mixed −72,924 — EDGAR
2025-07-21 LONNEL COATS Director Disp (D) −6,144 — EDGAR
2025-07-21 Debra Durso-Bumpus Chief People Officer Mixed −49,606 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
25 insiders · @ $129.46
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Third Rock Ventures II, L.P. 10%+ Owner 6,653,753 $861.39M $0 1 2015-11-18
2 KEVIN P STARR 10%+ Owner 5,453,753 $706.04M -$3.00M 3 2016-12-21
3 MARK J LEVIN 10%+ Owner 3,570,197 $462.20M -$1.23M 1 2017-03-20
4 ROBERT I TEPPER 10%+ Owner 3,453,753 $447.12M -$211.65M 2 2017-02-28
5 FMR LLC 10%+ Owner 496,813 $64.32M -$16.84M 8 2015-11-30
6 DANIEL LYNCH Director 127,904 $16.56M -$5.84M 18 2020-06-26
7 Michael Landsittel Chief Financial Officer 94,277 $12.21M -$4.91M 23 2025-07-21
8 Tracey L McCain EVP & Chief Legal Officer 88,195 $11.42M -$6.09M 21 2025-07-21
9 Percy H. Carter Chief Scientific Officer 74,508 $9.65M -$1.94M 16 2025-07-21
10 Alexis Borisy Director 74,160 $9.60M -$2.01M 18 2025-07-21
11 Debra Durso-Bumpus Chief People Officer 70,959 $9.19M -$12.14M 22 2025-07-21
12 Nicholas Lydon Director 58,026 $7.51M -$13.83M 22 2024-06-14
13 Christoph Lengauer Chief Scientific Officer 56,657 $7.33M -$3.27M 6 2016-04-14
14 Anthony L. Boral Chief Medical Officer 38,147 $4.94M -$7.23M 16 2020-12-16
15 Christopher K. Murray CHIEF TECHNICAL OPERATIONS 33,853 $4.38M -$1.86M 17 2024-03-11
16 Marion Dorsch Chief Scientific Officer 22,828 $2.96M -$5.84M 19 2021-02-24
17 Christina Rossi Chief Operating Officer 20,628 $2.67M -$3.37M 28 2025-07-21
18 Lynn Seely Director 13,254 $1.72M $0 13 2025-07-21
19 Daniella Beckman Director 10,842 $1.40M $0 6 2025-07-21
20 John Tsai Director 8,742 $1.13M $0 5 2025-07-21
21 Habib J Dable Director 8,742 $1.13M $0 5 2025-07-21
22 George Demetri Director 5,822 $753.7K -$1.68M 16 2022-06-30
23 Charles A Jr Rowland Director 5,812 $752.4K -$3.40M 10 2021-06-04
24 Tango Therapeutics, Inc. Director 3,400 $440.2K $0 1 2021-12-10
25 L. Becker Hewes Chief Medical Officer 1,607 $208.0K -$7.70M 20 2025-07-21
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.